Alpha Tau Medical's CFO will present at investor conferences in May 2025, discussing the Alpha DaRT cancer therapy.
Quiver AI Summary
Alpha Tau Medical Ltd., a company specializing in innovative alpha-radiation cancer therapy, announced that CFO Raphi Levy will present at two investor conferences in May 2025. He will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20 in New York and will hold 1x1 meetings at the Lytham Partners Spring 2025 Investor Conference on May 29, which will be virtual. Alpha Tau, founded in 2016, focuses on developing the Alpha DaRT technology for treating solid tumors, utilizing a method that delivers radium-224 to selectively destroy cancer cells while minimizing damage to healthy tissue. Interested investors can arrange meetings through their conference representatives.
Potential Positives
- Alpha Tau Medical's participation in prominent investor conferences highlights the company’s commitment to engage with investors and potentially attract new funding.
- The announcement of CFO Raphi Levy presenting underscores the significance of Alpha DaRT as a novel cancer therapy, positioning the company as a leader in oncology therapeutics.
- Alpha DaRT’s advanced technology and focus on precision treatment of solid tumors may attract interest from investors looking for impactful health innovations.
Potential Negatives
- The press release lacks any financial performance indicators or updates on the company's market position, which may raise concerns among investors about transparency and the company's overall health.
- There is no mention of any recent advancements, partnerships, or clinical trial results, potentially indicating stagnation in product development and market competitiveness.
- The focus on upcoming investor conferences without highlighting any recent success stories or milestones may lead to investor skepticism about the company's current state and future prospects.
FAQ
What is Alpha Tau Medical Ltd. known for?
Alpha Tau Medical Ltd. is known for developing the innovative alpha-radiation cancer therapy Alpha DaRT® for treating solid tumors.
When will CFO Raphi Levy present at investor conferences?
CFO Raphi Levy will present at the H.C. Wainwright BioConnect Conference on May 20 and the Lytham Partners Conference on May 29, 2025.
What is the format of the investor conferences?
The H.C. Wainwright conference will feature a Fireside Chat, while the Lytham Partners conference will involve 1x1 meetings.
How can investors schedule meetings with Raphi Levy?
Investors can schedule 1x1 meetings with Raphi Levy by contacting their representatives from H.C. Wainwright and Lytham Partners.
What is Alpha DaRT technology?
Alpha DaRT is a treatment method that uses alpha-emitting radiation to target and destroy solid tumors while sparing surrounding healthy tissue.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
| Event: | H.C. Wainwright 3rd Annual BioConnect Investor Conference |
| Format: | Fireside Chat |
| Date: | May 20, 2025 |
| Time: | 3:30 – 4:00PM ET |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2025 Investor Conference |
| Format: | 1x1 Meetings |
| Date: | May 29, 2025 |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT ®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
